ovarian cancer – Medxy AI

Biomarker-Driven Precision in Low-Grade Serous Ovarian Cancer: pERK and MAPK Mutations as Predictors of Trametinib Efficacy

By Zhang Paul 01/12/2026

Highlights High tumour pERK expression (histoscore >140) is a significant predictor of prolonged progression-free survival…

news Oncology

Atezolizumab Plus Bevacizumab and Chemotherapy in Recurrent Ovarian Cancer: Two Phase III Trials Fall Short of Practice‑Changing Benefit

By MedXY 12/08/2025

Two randomized phase III trials tested adding atezolizumab to bevacizumab plus chemotherapy in recurrent ovarian cancer. Neither AGO‑OVAR 2.29/ENGOT‑ov34 (non‑platinum, platinum‑resistant) nor ATALANTE/ENGOT‑ov29 (platinum‑sensitive) met their primary PFS/OS objectives.

Clinical Updates news

Defining Clinical Effectiveness of Risk-Reducing Early Salpingectomy in High-Risk BRCA Carriers: Insights from the PROTECTOR Cohort

By MedXY 09/24/2025

This article discusses the application of the estimand framework to evaluate clinical effectiveness of risk-reducing early salpingectomy with delayed oophorectomy in women with high ovarian cancer risk due to BRCA mutations, based on data from the UK PROTECTOR study.

Clinical Updates OB/GYN & Women's Health Oncology Specialties

Metformin in Gynecologic Cancers: A Comprehensive Review of Evidence in Cervical, Ovarian, and Endometrial Cancer

By MedXY 09/16/2025

This review synthesizes recent evidence on metformin's therapeutic and prognostic roles in cervical, ovarian, and endometrial cancers, highlighting randomized trials, meta-analyses, and clinical outcomes with a focus on progression-free and overall survival.

news OB/GYN & Women's Health Oncology Specialties

Early Signs of Ovarian Cancer: Understanding the Three Common Areas of Itching and Common Misdiagnoses Among Women

By MedXY 08/07/2025

Ovarian cancer often presents subtle early symptoms like itching in the abdomen, genital area, and legs, which are frequently misinterpreted. Recognizing these signs is crucial for timely diagnosis and treatment.

Clinical Updates news OB/GYN & Women's Health Oncology Specialties

Relacorilant Plus Nab-Paclitaxel: A New Standard for Platinum-Resistant Ovarian Cancer?

By MedXY 08/03/2025

Relacorilant combined with nab-paclitaxel significantly improved progression-free and overall survival in platinum-resistant ovarian cancer, with a favorable safety profile, suggesting a potential new treatment standard.

Clinical Updates news Oncology Specialties

Ovarian Cancer Risk Peaks Shortly After New IBS Diagnosis: Clinical Implications and Evidence Review

By MedXY 07/31/2025

A new IBS diagnosis is associated with a transiently increased risk of ovarian cancer, especially within the first 6 months, emphasizing the need for heightened clinical vigilance.